A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36190329.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2626 and PMC identifier 10281013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy. See related article by Nash et al., p. 5121.
Medical subject headings
- Mesothelioma
- Mesothelioma, Malignant